Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Nanomedicine ; 11: 3849-57, 2016.
Article in English | MEDLINE | ID: mdl-27563243

ABSTRACT

Diseases caused by bacterial and fungal pathogens are among the major health problems in the world. Newer antimicrobial therapies based on novel molecules urgently need to be developed, and this includes the antimicrobial peptides. In spite of the potential of antimicrobial peptides, very few of them were able to be successfully developed into therapeutics. The major problems they present are molecule stability, toxicity in host cells, and production costs. A novel strategy to overcome these obstacles is conjugation to nanomaterial preparations. The antimicrobial activity of different types of nanoparticles has been previously demonstrated. Specifically, magnetic nanoparticles have been widely studied in biomedicine due to their physicochemical properties. The citric acid-modified manganese ferrite nanoparticles used in this study were characterized by high-resolution transmission electron microscopy, which confirmed the formation of nanocrystals of approximately 5 nm diameter. These nanoparticles were able to inhibit Candida albicans growth in vitro. The minimal inhibitory concentration was 250 µg/mL. However, the nanoparticles were not capable of inhibiting Gram-negative bacteria (Escherichia coli) or Gram-positive bacteria (Staphylococcus aureus). Finally, an antifungal peptide (Cm-p5) from the sea animal Cenchritis muricatus (Gastropoda: Littorinidae) was conjugated to the modified manganese ferrite nanoparticles. The antifungal activity of the conjugated nanoparticles was higher than their bulk counterparts, showing a minimal inhibitory concentration of 100 µg/mL. This conjugate proved to be nontoxic to a macrophage cell line at concentrations that showed antimicrobial activity.


Subject(s)
Anti-Infective Agents/pharmacology , Antifungal Agents/pharmacology , Citric Acid/pharmacology , Coated Materials, Biocompatible/pharmacology , Ferric Compounds/pharmacology , Manganese Compounds/pharmacology , Nanoparticles/chemistry , Peptides/pharmacology , Animals , Anti-Bacterial Agents/pharmacology , Antifungal Agents/chemistry , Candida albicans/drug effects , Candida albicans/growth & development , Cell Proliferation/drug effects , Escherichia coli/drug effects , Mice , Microbial Sensitivity Tests , Microbial Viability/drug effects , Nanoparticles/ultrastructure , RAW 264.7 Cells , Staphylococcus aureus/drug effects
2.
BMC Res Notes ; 3: 97, 2010 Apr 09.
Article in English | MEDLINE | ID: mdl-20380716

ABSTRACT

BACKGROUND: The gene coding for the uncharacterized protein PAB1135 in the archaeon Pyrococcus abyssi is in the same operon as the ribonuclease P (RNase P) subunit Rpp30. FINDINGS: Here we report the expression, purification and structural analysis of PAB1135. We analyzed the interaction of PAB1135 with RNA and show that it binds efficiently double-stranded RNAs in a non-sequence specific manner. We also performed molecular modeling of the PAB1135 structure using the crystal structure of the protein Af2318 from Archaeoglobus fulgidus (2OGK) as the template. CONCLUSIONS: Comparison of this model has lead to the identification of a region in PAB1135 that could be involved in recognizing double-stranded RNA.

SELECTION OF CITATIONS
SEARCH DETAIL
...